10% CALCIUM CHLORIDE INJECTION, USP 1gram (100mg/mL) SYR

Manufacturer
HF Acquisition Co LLC, DBA HealthFirst
Effective date
2024-01-29
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
full-release
Hydrated at
2026-05-31 20:59:01

Label at a glance#

ProductCALCIUM CHLORIDE
Active ingredientCALCIUM CHLORIDE
Label structure17 sections

Label contents#

Full prescribing information#

SPL UNCLASSIFIED

SPL UNCLASSIFIED SECTION

100 mg/mL Rx only
Represents 27 mg (1.4 mEq) Ca++/mL
ABBOJECT® Syringe
A HYPERTONIC SOLUTION IN A 10 ML
UNIT OF USE SYRINGE FOR PROMPT
INTRAVENOUS INJECTION.
CAUTION: This solution must not be injected
intramuscularly or subcutaneously.

DESCRIPTION

DESCRIPTION SECTION

10% Calcium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution containing 100 mg (1.4 mEq/mL) of calcium chloride, dihydrate (1.4 mEq each of Ca++ and Cl¯) in water for injection. It is provided in a 10 mL Unit of Use Syringe to facilitate prompt intravenous injection. The solution is administered only by intravenous or intraventricular cavity injection as a calcium replenisher.

The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. As per USP testing, when diluted with water for injection to make a 5% solution, the pH of calcium chloride injection is 6.3 (5.5 to 7.5). May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. The osmolar concentration is 2.04 mOsmol/mL (calc.). 10% Calcium Chloride Injection, USP is oxygen sensitive.

Calcium Chloride, USP dihydrate is chemically designated CaCl2 · 2H2O (dihydrate) white, odorless fragments or granules freely soluble in water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Calcium is the fifth most abundant element in the body and the major fraction is in the bony structure. Calcium plays important physiological roles, many of which are poorly understood. It is essential for the functional integrity of the nervous and muscular systems. It is necessary for normal cardiac function and is one of the factors that operates in the mechanisms involved in the coagulation of blood.

Calcium chloride in water dissociates to provide calcium (Ca++) and chloride (Cl¯) ions. They are normal constituents of the body fluids and are dependent on various physiological mechanisms for maintenance of balance between intake and output. Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

INDICATIONS & uSAGE

INDICATIONS & USAGE SECTION

10% Calcium Chloride Injection, USP is indicated (1) for the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, (2) in the treatment of magnesium intoxication due to overdosage of magnesium sulfate and (3) to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid.

10% Calcium Chloride Injection, USP also may be used in cardiac resuscitation when weak or inadequate contractions return following defibrillation or when epinephrine injection has failed to strengthen myocardial contractions.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Calcium chloride is contraindicated for cardiac resuscitation in the presence of ventricular fibrillation or in patients with the risk of existing digitalis toxicity.

WARNINGS

WARNINGS SECTION

10% Calcium Chloride Injection, USP is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur. Great care should be taken to avoid extravasation or accidental injection into perivascular tissues.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

PRECAUTIONS SECTION

Do not administer unless solution is clear and seal is intact. Discard unused portion.

Because of its additive effect, calcium should be administered very cautiously to a patient who is digitalized or who is taking effective doses of digitalis or digitalis-like preparations.

Injections should be made slowly through a small needle into a large vein to minimize venous irritation and avoid undesirable reactions. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope. If injected into the ventricular cavity in cardiac resuscitation, it must not be injected into the myocardial tissue.

Pregnancy: Animal reproduction studies have not been conducted with calcium chloride. It also is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Calcium chloride should be given to a pregnant woman only if clearly needed.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Rapid injection may cause the patient to complain of tingling sensations, a calcium taste, a sense of oppression or “heat wave”.

Injections of calcium chloride are accompanied by peripheral vasodilatation as well as a local “burning” sensation and there may be a moderate fall in blood pressure.

Should perivascular infiltration occur, I.V. administration at that site should be discontinued at once. Local infiltration of the affected area with 1% procaine hydrochloride, to which hyaluronidase may be added, will often reduce venospasm and dilute the calcium remaining in the tissues locally. Local application of heat may also be helpful.

DRUG ABUSE & DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

None known.

DOSAGE & ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

10% Calcium Chloride Injection, USP is administered only by slow intravenous injection (not to exceed 1 mL/min) and/or in cardiac resuscitation, by injection into the ventricular cavity. It must not be injected into the myocardium.

The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.

The usual adult dosage in hypocalcemic disorders ranges from 500 mg to 1 g (5 to 10 mL) at intervals of 1 to 3 days, depending on the response of the patient and/or results of serum calcium determinations. Repeated injections may be required because of rapid excretion of calcium.

In magnesium intoxication, an initial adult dose of 500 mg (5 mL) should be administered promptly and the patient observed for signs of recovery before further doses are given.

In hyperkalemic ECG disturbances of cardiac function, the dosage of calcium chloride injection should be titrated by constant monitoring of ECG changes during administration.

In cardiac resuscitation, the usual adult dosage ranges from 500 mg to 1 g (5 to 10 mL) intravenously, or from 200 to 800 mg (2 to 8 mL) when injected into the ventricular cavity.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

To prevent needle-stick injuries, needles should not be recapped, purposely bent or broken by hand.

OVERDOSAGE

OVERDOSAGE SECTION

oo rapid injection may produce lowering of blood pressure and cardiac syncope. Persistent hypercalcemia from overdosage of calcium is unlikely because of rapid excretion. In the event of untoward effects from excessive calcium administration, the drug should be discontinued promptly, the patient re-evaluated and appropriate countermeasures instituted, if necessary. See PRECAUTIONS and ADVERSE REACTIONS.

HOW SUPPLIED

HOW SUPPLIED SECTION

10% CALCIUM CHLORIDE INJECTION is supplied in the following dosage forms.
NDC 51662-1209-1
10% CALCIUM CHLORIDE INJECTION, USP 1gram (100mg/mL) SYR

NDC 51662-1209-2
10% CALCIUM CHLORIDE INJECTION, USP 1gram (100mg/mL) SYR, 1 SYRINGE PER POUCH

NDC 51662-1209-3

10% CALCIUM CHLORIDE INJECTION, USP 1gram (100mg/mL) SYR, 1 SYRINGE PER POUCH, 10 POUCHES PER CASE

HF Acquisition Co LLC, DBA HealthFirst
Mukilteo, WA 98275

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Abboject® is a trademark of the Abbott group of companies

LIFESHIELD® is the trademark of ICU Medical, Inc.

PRINCIPLE DISPLAY PANEL, SYRINGE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

CALCIUM CHLORIDE 1 Gram/10 mL

10 mL Single-dose
NDC 0409-4928-34

10% CALCIUM CHLORIDE Inj., USP
1 Gram (100 mg/mL)
1.4 mEq Ca++/mL

For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic.
Caution: Do not inject intramuscularly or subcutaneously.
2.04 mOsmol/mL (calc.). pH 6.3 (5.5 to 7.5).
Contains no more than 1000 mcg/L of aluminum.

Rx only

Hospira

Hospira, Inc.
Lake Forest, IL 60045 USA

RL-0680 (10/04)

SYRINGE LABELSYRINGE LABEL

PRINCIPLE DISPLAY PANEL, CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

10 mL

NDC 0409-4928-34

10%
CALCIUM
CHLORIDE
Injection, USP

1 gram (100 mg/mL)
represents 27 mg
(1.4 mEq) Ca++/mL

LifeShield®

Glass
ABBOJECT®
Unit of Use Syringe

with male luer lock adapter and
20-Gauge protected needle

Rx only

Hospira

◀ PRESS AND PULL TO OPEN

CARTONCARTON

PRINCIPLE DISPLAY PANEL, SERIALIZED LABEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

SERIALIZED CARTONSERIALIZED CARTON

PRINCIPAL DISPLAY PANEL - NDC 51662-1209-2 POUCH LABELING

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51662-1209-2 POUCH LABELING

POUCH LABELINGPOUCH LABELING

CARTON LABELING

CARTON LABELINGCARTON LABELING

SYRINGE LABEL

SYRINGE LABELSYRINGE LABEL

PRINCIPAL DISPLAY PANEL - NDC 51662-1209-3 CASE LABELING

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51662-1209-2 CASE LABELING

Case LabelingCase Labeling

SERIALIZED CASE RFID LABELING

RFID LabelRFID Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
828527calcium chloride 10 % in 10 ML Prefilled SyringePSN6
82852710 ML calcium chloride 100 MG/ML Prefilled SyringeSCD6
828527calcium chloride 10 % in 10 ML Prefilled SyringeSY6

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
bee4fa8d-8d82-423a-a0b5-40a89dd13a99Product name120250618
e0d2eb29-08bd-4bba-90d1-c91c68a38767Product name420250516
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
334fe8d2-68fb-4331-a576-420e302ec069Product name720240320
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
e92765c1-be81-432a-b909-1b10777ec378Product name120190208
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
0441a8f5-3835-497c-aedd-bc78cba56b2aProduct name120150317
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
51662-1209-1CALCIUM CHLORIDE1 in 1 CARTONINJECTION, SOLUTION16
51662-1209-1CALCIUM CHLORIDE10 mL in 1 SYRINGE, GLASSINJECTION, SOLUTION106
51662-1209-2CALCIUM CHLORIDE1 in 1 POUCHINJECTION, SOLUTION16
51662-1209-2CALCIUM CHLORIDE1 in 1 CARTONINJECTION, SOLUTION16
51662-1209-3CALCIUM CHLORIDE10 in 1 CASEINJECTION, SOLUTION106

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
51662-1209CALCIUM CHLORIDE INJECTION, SOLUTION [HF ACQUISITION CO LLC, DBA HEALTHFIRST]6Current NDC, Legacy NDC, 5 package rows20240131_75c43df8-24f4-7f26-e053-2a91aa0aa21b.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0409-4928-34ML - Milliliter0409-4928cea32b8c-47f3-4301-bdd3-49e0b3a987d112013-05-02

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51662-120951662-1209-1, 51662-1209-2, 51662-1209-3
0409-4928

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CALCIUM CHLORIDECALCIUM CHLORIDEHF Acquisition Co LLC, DBA HealthFirst75c43df8-24f4-7f26-e053-2a91aa0aa21b2024-01-29Warnings, Adverse reactionsExact identifier
ndc (package): 51662-1209-1
ndc (package): 51662-1209-3
ndc (package): 51662-1209-2
ndc (product): 51662-1209
ndc11 (package): 51662120901
ndc11 (package): 51662120902
ndc11 (package): 51662120903
spl id: 101ed6d9-3acd-389d-e063-6394a90aaada
spl set id: 75c43df8-24f4-7f26-e053-2a91aa0aa21b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.